Elsevier

Drug Discovery Today

Volume 25, Issue 9, September 2020, Pages 1604-1613
Drug Discovery Today

Review
Keynote
Learning from history: do not flatten the curve of antiviral research!

https://doi.org/10.1016/j.drudis.2020.07.008Get rights and content

Highlights

  • COVID-19 has caused the most rapid research response to a pandemic in recent history.

  • After epidemics end, less research is performed on the causative agent.

  • Except for HIV/AIDS, responses to previous epidemics have yielded no new antivirals.

  • Consistent funding for antiviral research is needed to prepare for future epidemics.

Here, we explore the dynamics of the response of the scientific community to several epidemics, including Coronavirus Disease 2019 (COVID-19), as assessed by the numbers of clinical trials, publications, and level of research funding over time. All six prior epidemics studied [bird flu, severe acute respiratory syndrome (SARS), swine flu, Middle East Respiratory Syndrome (MERS), Ebola, and Zika] were characterized by an initial spike of research response that flattened shortly thereafter. Unfortunately, no antiviral medications have been discovered to date as treatments for any of these diseases. By contrast, the HIV/AIDS pandemic has garnered consistent research investment since it began and resulted in drugs being developed within 7 years of its start date, with many more to follow. We argue that, to develop effective treatments for COVID-19 and be prepared for future epidemics, long-term, consistent investment in antiviral research is needed.

Cited by (0)

Eugene N. Muratov is a research associate professor and associate director of the Laboratory for Molecular Modeling at the UNC Eshelman School of Pharmacy, UNC-Chapel Hill. He was awarded an MSc in the technology of organic substances from Odessa National Polytechnic University in 2000 and a PhD in organic chemistry in 2004 from the A.V. Bogatsky Physical-Chemical Institute. From 2014 to 2020, he was a visiting professor at the Federal Universities of Goias and Paraiba, Brazil. His research interests are in the areas of cheminformatics (especially QSAR), computer-assisted drug design, antiviral research, computational toxicology, and medicinal chemistry. He has co-authored ∼130 peer-reviewed publications and edited two books.

Alexander Tropsha is a K.H. Lee distinguished professor and associate dean for data science at the UNC Eshelman School of Pharmacy, UNC-Chapel Hill. Professor Tropsha was awarded a PhD in chemical enzymology in 1986 from Moscow State University. His research interests are in the areas of computer-assisted drug design, computational toxicology, cheminformatics, (nano)materials informatics, and structural bioinformatics. His has authored ∼250 peer-reviewed scientific papers, book chapters, and co-edited two monographs. His research has been supported by multiple grants from the NIH, NSF, EPA, DOD, foundations, and private companies.

View Abstract